옵션 체인은 다양한 행사가격과 만기일에 대한 Evolent Health의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Evolent Health에 대한 시장 심리를 평가합니다..

Evolent Health (NYSE:EVH) 주식, 옵션 체인

Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

ASTSpaceMobile.Screenshotvideo

Asia

Mid Cap

News

Movers

ASTS

IOVA

LUMN

PSNY

SFTBF

SMTC

UPST

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요? 1. 폴스타 오토모티브 홀딩(NASDAQ:PSNY)의 주식이 8월에 74.19% 급등했다. 이는 2분기 강력한 인도량을 발표한 후 발생한 일이다.

AST 스페이스모바일 및 폴스타는 8월에 최고 성과를 보여준 10개 중형주 중 일부

Evolent Health Inc

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Morgan Stanley ETF Trust Eaton Vance High Yield ETF

Analysts' ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.89, a high estimate of $16.00, and a low estimate of $12.00. A 0.79% drop is evident in the current average compared to the previous average price target of $14.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746828039_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolent Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Evolent Health's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.27%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Evolent Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.0% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.21%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.71.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Evolent Health Through The Eyes Of 9 Analysts

UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and raises the price target from $14 to $15.

Price Target

UBS Maintains Buy on Evolent Health, Raises Price Target to $15

WIIM

Evolent Health shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results and issued Q2 sales guidance below estimates.

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) affirms FY2025 sales outlook from $2.06 billion-$2.11 billion to $2.06 billion-$2.11 billion vs $2.07 billion estimate.

Guidance

Evolent Health Affirms FY2025 Sales Guidance of $2.06B-$2.11B vs $2.07B Est

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) sees Q2 sales of $440.000 million-$470.000 million vs $502.11 million analyst estimate.

Evolent Health Sees Q2 Sales $440.000M-$470.000M vs $502.11M Est

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.10 by 40 percent. This is a 82.35 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $483.65 million which beat the analyst consensus estimate of $460.31 million by 5.07 percent. This is a 24.39 percent decrease over sales of $639.65 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Evolent Health Q1 Adj. EPS $0.06 Misses $0.10 Estimate, Sales $483.65M Beat $460.31M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

JMP Securities analyst Constantine Davides reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and maintains $13 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Evolent Health, Maintains $13 Price Target

<ul>
<li>Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain.</li>
<li>Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens.</li>
<li>One low-value regimen costs about 70 times more than a clinically equivalent alternative.</li>
</ul>
WASHINGTON, April 15, 2025 /PRNewswire/ -- When treating patients with cancer, oncologists typically can choose from multiple FDA-approved regimens, or combinations of drugs.
While tools such as Evolent's clinical pathways can help them find high-value options, providers have not had similar resources to flag regimens on the opposite side of the spectrum. These other regimens may be associated with lower survival, more severe side effects, or extremely high cost without additional clinical benefits.
Today, in the Journal of Clinical Pathways, Evolent oncology experts <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4405248-1&amp;h=1442647278&amp;u=https%3A%2F%2Fwww.hmpgloballearningnetwork.com%2Fsite%2Fjcp%2Ffield%2Fturning-pathways-their-head-deimplementation-low-value-treatment-regimens&amp;a=reported">reported</a> on their efforts to identify these "low-value regimens" and then decrease their use by more than 20%, following a multifaceted provider education and engagement campaign with a national payer partner.
"For oncologists, selecting between available treatment options can be a close call, but there are certain regimens that miss by a wide margin," said Evolent CMO Emeritus and Senior Advisor Dr. Andrew Hertler. "While low-value options represent a tiny percentage of cancer drugs ordered, avoiding them can have an outsize impact on both the quality and affordability of care for patients. Given that medications are the largest component of spending on cancer care — about 60 percent for Medicare populations — we need to ensure we are investing in therapies that offer patients the greatest promise for longer, better lives."
The low-value regimen program spans therapies across 10 common cancer types, representing about 1 percent of all requests that Evolent receives. Each regimen was identified by Evolent clinical experts after a thorough examination of the medical literature, as well as real-world outcomes. They were then reviewed and approved by the company's Oncology Scientific Advisory Board, which consists of leading community and academic oncologists from across the U.S.
The Evolent team found dramatic differences between high- and low-value regimens. For example, one low-value lung cancer regimen is about 70 times more expensive — or $40,000 more per quarter — than a preferred alternative. Yet the evidence to date does not support that it offers better clinical outcomes.
In early 2023, Evolent and a national health plan partner embarked on a multifaceted campaign to voluntarily reduce use of these regimens in multiple markets. Outreach included provider awareness efforts, such as in-person and virtual forums where Evolent oncology pharmacists reviewed the evidence with practice-based clinicians. White papers and videos also supported the education effort.
Leveraging technology, Evolent also flagged low-value regimens as non-preferred in its clinical decision support system. If a provider still requested one of these therapies, it triggered outreach from an Evolent clinical reviewer, who sought to understand the particulars of the case, go over the evidence, and explore higher-value options the provider could voluntarily switch to.
Evolent also administered pay-for-performance programs that incentivize providers for using preferred regimens while de-incentivizing low-value options. And the use of low-value regimens was a key metric on specialist scorecards that Evolent disseminates to oncology practices and referring providers.
From February through May 2024, the use of low-value regimens decreased by 20.1%, compared to the same four-month period in 2023. That change was driven in large part by shifts in ordering habits — provider requests for low-value regimens dropped by 15.5 percent.&nbsp;
"The low-value regimen program showcases the power of our provider engagement model to drive change," said Evolent Chief Medical Officer Dr. Von Nguyen. "Increasing providers' awareness of low-value regimens is a critical piece of the puzzle, requiring multiple touchpoints and real relationships built on trust. Still, awareness alone is not enough. We leverage technology, performance reporting and the right incentive structures to keep these issues top of mind and sustain improvement over the long term."
Evolent's low-value regimen program is now active with health plans across the U.S.

Evolent Announces Program Achieves 20% Reduction In Use Of Low-Value Oncology Regimens. Program Active With Health Plans Across The U.S.

In the latest quarter, 16 analysts provided ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.81, a high estimate of $20.00, and a low estimate of $12.00. This current average has decreased by 17.45% from the previous average price target of $17.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1744293635_0_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Evolent Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $14.00&#x7C;$15.00 &#x7C; 
&#x7C;Anne Samuel &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;Constantine Davides &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $13.00&#x7C;$12.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $16.00&#x7C;$17.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $12.00&#x7C;$12.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Anne Samuel &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $13.00&#x7C;$15.00 &#x7C; 
&#x7C;Jeff Jones &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $18.00&#x7C;$28.00 &#x7C; 
&#x7C;Richard Close &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $16.00&#x7C;$23.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $15.00&#x7C;$20.00 &#x7C; 
&#x7C;Jeff Garro &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $12.00&#x7C;$16.00 &#x7C; 
&#x7C;Kevin Caliendo &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $14.00&#x7C;$27.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $17.00&#x7C;$20.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $20.00&#x7C;$24.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Evolent Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Evolent Health Better</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Evolent Health's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.27%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -4.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Evolent Health's ROA excels beyond industry benchmarks, reaching -1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Evolent Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.71.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Evolent Health In The Eyes Of 16 Experts

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $15 to $14.

Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $14

On Monday, the U.S. Centers for Medicare &amp; Medicaid Services (CMS) released its 2026 payment update for Medicare Advantage (MA) and Medicare Part D <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">prescription drug plans</a>.
Government <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-2026-payment-policy-updates-medicare-advantage-and-part-d-programs" target="_blank" rel="noreferrer noopener">payments</a> to Medicare Advantage plans are expected to rise by an average of 5.06% from 2025 to 2026. That&#8217;s 2.83 percentage points higher than what was estimated in a previous notice. 
The new effective growth rate is 9.04%, up from the earlier estimate of 5.93%.
The increase comes from updated data on traditional Medicare (fee-for-service) spending. This includes figures from late 2024 that weren&#8217;t available when the earlier notice was published.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/25/04/44672618/trump-tariffs-to-hurt-nike-under-armour-vf-are-ralph-lauren-foot-locker-safer-bets" rel="noreferrer noopener">Trump Tariffs To Hurt Nike, Under Armour, VF: Are Ralph Lauren, Foot Locker Safer Bets?</a>
CMS also began a three-year plan in 2024 to remove medical education costs from the fee-for-service spending data for setting MA rates. For 2026, CMS will fully implement this adjustment.
In addition, CMS is continuing a three-year rollout of changes to how it adjusts payments based on enrollee health risks, a process that began in 2024.
According to William Blair, the better-than-expected rate update is a &#8220;clear positive&#8221; for Medicare Advantage. The managed care group struggles to maintain medical loss ratios. 
In William Blair&#8217;s coverage, Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) is most directly impacted. Analyst Ryan Daniels also sees favorable implications for the broader value-based care universe.
&#8220;In particular, we believe that our covered advanced primary care (APC) companies are set to benefit from these improving MA trends,&#8221; analyst Daniels writes.
William Blair writes that notable players focusing solely on the MA market include Agilon Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) and P3 Health Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>).
&#8220;Other VBC names, with broader payer exposure (typically working with all payer types, though still caring for MA patients) could also benefit from better industry trends,&#8221; William Blair writes.
The analyst notes some players, including Privia Health Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>), Astrana Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>), and Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>).
Price Action: ALHC stock is up 10.5% at $19.69 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44673238/apple-faces-eps-hit-from-tariffs-while-doubleverify-and-viant-stay-shielded-with-virtual-revenue-models-analyst" target="_blank" rel="noreferrer noopener">Analyst Forecasts Tariffs Impact On Apple&#8217;s Profit And Highlights 2 Software Stocks That Are Safeguards</a></li>
</ul>
Image: Shutterstock

Government

Large Cap

Regulations

Health Care

Trading Ideas

General

ALHC

PIII

PRVA

Medicare Advantage Rates Expected To Climb Over 5% In 2026, Easing Pressure On Managed Care

Throughout the last three months, 18 analysts have evaluated Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.22, along with a high estimate of $20.00 and a low estimate of $12.00. Highlighting a 19.13% decrease, the current average has fallen from the previous average price target of $18.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640658_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Evolent Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Evolent Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.27% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Evolent Health's debt-to-equity ratio is below the industry average at 0.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 18 Analysts Discuss Evolent Health Stock

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $13 to $12.

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $12

Citizens Capital Markets analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and raises the price target from $12 to $13.

Citizens Capital Markets Maintains Market Outperform on Evolent Health, Raises Price Target to $13

Piper Sandler analyst Jessica Tassan reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $17 to $16.

Piper Sandler Reiterates Overweight on Evolent Health, Lowers Price Target to $16

Needham analyst Ryan MacDonald reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $15 price target.

Needham Reiterates Buy on Evolent Health, Maintains $15 Price Target

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 300 percent. This is a 108.7 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $646.50 million which missed the analyst consensus estimate of $651.19 million by 0.72 percent. This is a 16.27 percent increase over sales of $556.05 million the same period last year.

Evolent Health Q4 2024 Adj EPS $(0.02) Misses $0.01 Estimate, Sales $646.50M Miss $651.19M Estimate

Evolent Sees FY25 Revenue $2.06B-$2.11B

ACCO

ARDX

AXTI

BABA

BAND

BBIO

BILI

BIRK

BJRI

BKNG

BLDR

CDRO

CELH

CENX

CERS

CGAU

Earnings Scheduled For February 20, 2025

Comments

Evolent Health

Evolent Health (EVH) 옵션

Evolent Health (NYSE:EVH) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌